David Kerr

DMC Biostatistician Director

David Kerr is a DMC Biostatistician Director at Cytel. He has dedicated 28 years to Axio Research, a Cytel company. David is a leader in Axio’s DMC services, which facilitate more than 500 DMC meetings annually. He played an instrumental role in developing SOPs that govern Axio’s DMC services. In addition to his duties as DMC Biostatistician Director, David has provided statistical support as the reporting statistician for more than 250 DMCs covering 300 individual clinical trials. His expertise spans disease areas such as oncology, cardiology, infectious disease, respiratory disease, and rheumatology. He has attended over 1000 DMC meetings, becoming a strong advocate for improving DMC processes. He regularly presents at conferences and conducts industry tutorials to ensure DMCs are equipped with the best information to make educated recommendations, prioritizing both trial success and participant safety.

David received his Master’s in Statistics from the University of Washington and is based in Seattle, Washington.

David Kerr

Related Articles

What it Takes to Be a DMC Member
Blog
octobre 31, 2024
What it Takes to Be a DMC Member
Read More
Understanding the Critical Role of DMCs in Oncology Studies
Blog
août 22, 2024
Understanding the Critical Role of DMCs in Oncology Studies
Read More
Data Monitoring Committees for Phase 1 Clinical Trials
Blog
mai 30, 2024
Data Monitoring Committees for Phase 1 Clinical Trials
Read More
The FDA’s New Draft Guidance on DMCs: What to Know
Blog
avril 2, 2024
The FDA’s New Draft Guidance on DMCs: What to Know
Read More